Therefore, simultaneously inducing KSHV reactivation and inhibiting antiapoptosis has been widely studied for the treatment of PEL; this included the use of nutlin-3 (24, 46), cisplatin (47, 48), silver nanoparticle (nAg) (49), cyclin-dependent kinase 1 (Cdk1) inhibitor (50), and histone deacetylase (HDAC) inhibitor (17, 18, 38). The gene discussed is HDAC9; the disease is primary effusion lymphoma.